These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17373284)

  • 1. [Recommendations of iron management in chronic kidney patients].
    Canaud B
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S356-62. PubMed ID: 17373284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and iron.
    Sunder-Plassmann G; Hörl WH
    Clin Nephrol; 1997 Mar; 47(3):141-57. PubMed ID: 9105761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
    Garneata L
    J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Issues related to iron replacement in dialyzed patients].
    Kessler M
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron management in hemodialysis patients: optimizing outcomes in Vicenza, Italy.
    Crepaldi C; Brendolan A; Bordoni V; Carta MR; D'Intini V; Gastaldon F; Inguaggiato P; Ronco C
    Hemodial Int; 2003 Jun; 7(3):216-21. PubMed ID: 19379368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients.
    Kovesdy CP
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):109-16. PubMed ID: 19233070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron metabolism in rhEPO-treated hemodialysis patients.
    Schaefer RM; Bahner U
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S65-8. PubMed ID: 10746809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron requirements in erythropoietin therapy.
    Eschbach JW
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):347-61. PubMed ID: 15737895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing iron status: beyond serum ferritin and transferrin saturation.
    Wish JB
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients.
    Kim JM; Ihm CH; Kim HJ
    Int J Lab Hematol; 2008 Feb; 30(1):46-52. PubMed ID: 18190467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.